Mirum Pharmaceuticals
↗Foster City, USA
Mirum Pharmaceuticals is a commercial-stage biopharmaceutical company dedicated to transforming the treatment of rare diseases, with a primary focus on debilitating liver conditions. Founded in 2018, the company has rapidly built a portfolio of approved therapies and a robust clinical pipeline targeting cholestatic liver diseases and other rare disorders.
The company's flagship product, LIVMARLI (maralixibat), is an oral ileal bile acid transporter (IBAT) inhibitor approved for the treatment of cholestatic pruritus in patients with Alagille syndrome and Progressive Familial Intrahepatic Cholestasis (PFIC). Mirum also markets Cholbam and Ctexli, which were acquired to strengthen its position in the rare liver disease market.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Revenue:$472M (TTM)
Founded:2018
Ownership:public
Status:operating
FUNDING
Stage:Public
Total Raised:$120M
Investors:New Enterprise Associates, Frazier Healthcare Partners, Deerfield Management, TCG Crossover
STOCK
Exchange:NASDAQ
Ticker:MIRM
Market Cap:$6.3B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, mAb
Active Trials:35
Trial Phases:Phase 1: 5 | Phase 2: 15 | Phase 3: 10 | Phase 4: 5
FDA Approvals:3
EMA Approvals:1
CORPORATE STRUCTURE
Subsidiaries:Bluejay Therapeutics, Satiogen
Key Partnerships:Takeda (Licensing for maralixibat in Japan), GC Biopharma (Licensing in South Korea)
COMPETITION
Position:Leader
Competitors:Ultragenyx, Ipsen (Albireo), Intercept Pharmaceuticals, UniQure
LEADERSHIP
Key Executives:
Chris Peetz - CEO
Peter Radovich - President & COO
Scientific Founders:Chris Peetz, Niall O'Donnell, Michael Grey
Board Members:Michael Grey (Chairman), Laura Brege, Patrick Heron, Tim Walbert
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Mirum Pharmaceuticals. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.